In this issue:
Rivaroxaban vs. LMWH in cancer-associated VTE
Prediction model for cancer-associated VTE
CRP and VTE risk
Treatment intensification with SCT + lenalidomide in new myeloma
Parameters related to leukaemic progression in lower-risk MDS
Plasma cell proliferative index predicts outcomes in SCT-treated AL amyloidosis
Bortezomib therapy, then SCT, improves outcomes in AL amyloidosis
Venetoclax for CLL with del(17p)
Switching to dasatinib for imatinibrelated low-grade adverse events in CML
Please login below to download this issue (PDF)